These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28890480)

  • 21. Survival of Japanese patients with pulmonary arterial hypertension after the introduction of endothelin receptor antagonists and/or phosphodiesterase type-5 inhibitors.
    Sakao S; Tanabe N; Kasahara Y; Tatsumi K
    Intern Med; 2012; 51(19):2721-6. PubMed ID: 23037462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epoprostenol Therapy for Pulmonary Arterial Hypertension.
    Akagi S; Nakamura K; Matsubara H; Ogawa A; Sarashina T; Ejiri K; Ito H
    Acta Med Okayama; 2015; 69(3):129-36. PubMed ID: 26101188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
    Suleman N; Frost AE
    Chest; 2004 Sep; 126(3):808-15. PubMed ID: 15364760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The current pharmacotherapy of pulmonary arterial hypertension].
    Betkier-Lipińska K; Ryczek R; Cwetsch A
    Pol Merkur Lekarski; 2015 Jan; 38(223):34-8. PubMed ID: 25763586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination therapy in pulmonary arterial hypertension.
    Pugh ME; Hemnes AR; Robbins IM
    Clin Chest Med; 2013 Dec; 34(4):841-55. PubMed ID: 24267308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulmonary arterial hypertension in children: a medical update.
    Rosenzweig EB; Barst RJ
    Indian J Pediatr; 2009 Jan; 76(1):77-81. PubMed ID: 19391006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [What is new in the treatment of pulmonary artery hypertension?].
    Pulido Zamudio T
    Arch Cardiol Mex; 2003; 73 Suppl 1():S121-4. PubMed ID: 12966661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-related pulmonary arterial hypertension: clinical presentation and management.
    Sitbon O
    AIDS; 2008 Sep; 22 Suppl 3():S55-62. PubMed ID: 18845923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
    Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
    Ann Am Thorac Soc; 2015 Feb; 12(2):269-73. PubMed ID: 25590376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of pulmonary arterial hypertension].
    Jaïs X; Bonnet D
    Presse Med; 2010 Jun; 39 Suppl 1():1S22-32. PubMed ID: 20732614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
    Beghetti M; Galiè N
    J Am Coll Cardiol; 2009 Mar; 53(9):733-40. PubMed ID: 19245962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of Pulmonary Arterial Hypertension.
    Weatherald J; Varughese RA; Liu J; Humbert M
    Semin Respir Crit Care Med; 2023 Dec; 44(6):746-761. PubMed ID: 37369218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension.
    Langleben D; Barst RJ; Badesch D; Groves BM; Tapson VF; Murali S; Bourge RC; Ettinger N; Shalit E; Clayton LM; Jöbsis MM; Blackburn SD; Crow JW; Stewart DJ; Long W
    Circulation; 1999 Jun; 99(25):3266-71. PubMed ID: 10385501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current issues in pulmonary hypertension].
    Forster T
    Orv Hetil; 2012 Apr; 153(16):603-6. PubMed ID: 22510315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.
    Demerouti E; Karyofyllis P; Manginas A; Anthi A; Karatasakis G; Athanassopoulos G; Voudris V
    Am J Cardiovasc Drugs; 2019 Apr; 19(2):99-105. PubMed ID: 30671881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on pulmonary arterial hypertension pharmacotherapy.
    Velayati A; Valerio MG; Shen M; Tariq S; Lanier GM; Aronow WS
    Postgrad Med; 2016 Jun; 128(5):460-73. PubMed ID: 27232660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
    Humbert M; Barst RJ; Robbins IM; Channick RN; Galiè N; Boonstra A; Rubin LJ; Horn EM; Manes A; Simonneau G
    Eur Respir J; 2004 Sep; 24(3):353-9. PubMed ID: 15358690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.
    Jacobs W; Boonstra A; Brand M; Rosenberg DM; Schaaf B; Postmus PE; Vonk Noordegraaf A
    J Heart Lung Transplant; 2010 Oct; 29(10):1150-8. PubMed ID: 20580264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension.
    Chin KM; Channick RN; de Lemos JA; Kim NH; Torres F; Rubin LJ
    Chest; 2009 Jan; 135(1):130-136. PubMed ID: 18719056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.